5 Key Takeaways

• 1

  Presbyopia drops serve as a strategic entry point into lifelong eye care, addressing immediate concerns while fostering long-term patient relationships.

• 2

  Currently, three presbyopia drops are FDA-approved: Qlosi, Vuity, and Vizz, providing non-surgical alternatives for early-to-moderate presbyopes.

• 3

  Customizability of presbyopia drops allows flexible dosing, empowering patients to manage their vision based on personal needs and lifestyles.

• 4

  Clear communication about the temporary nature of presbyopia drops and the importance of neuroadaptation enhances patient satisfaction and retention.

• 5

  Early engagement with presbyopia drops encourages proactive patient involvement in eye care, improving long-term outcomes and satisfaction.